CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates
- 1 March 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 10 (2) , 95-104
- https://doi.org/10.1097/00008571-200003000-00001
Abstract
To assess the effects of Ile359 to Leu359 change on CYP2C9-mediated metabolism, we performed site-directed mutagenesis and cDNA expression in yeast for CYP2C9 and examined in detail the kinetics of seven metabolic reactions by wild-type CYP2C9 (Ile359) and its Leu359 variant. For the metabolism of all the substrates studied, the Leu359 variant exhibited smaller V max/ K m values than did the wild-type. The differences in the V max/ K m values between the wild-type and the Leu359 variant varied from 3.4-fold to 26.9-fold. The Leu359 variant had higher K m values than did the wild-type for all the reactions studied. Among the seven reactions studied, the greatest difference in the V max values between the wild-type and the Leu359 variant was for piroxicam 5′-hydroxylation (408 versus 19 pmol/min/nmol P450), whereas there were no differences in the V max values between the wild-type and the Leu359 variant for diclofenac 4′-hydroxylation and tolbutamide methylhydroxylation. These results indicate that the Ile359 to Leu359 change significantly decreases the catalytic activity of all the CYP2C9-mediated metabolisms studied, whereas the extent of the reduction in activity and changes of the kinetic parameters varies between substrates. Moreover, the amino acid substitution decreased the enantiomeric excess in the formation of 5-(4-hydroxyphenyl)-5-phenylhydantoin from phenytoin.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allelePharmacogenetics, 1999
- Identification of Residues 286 and 289 as Critical for Conferring Substrate Specificity of Human CYP2C9 for Diclofenac and IbuprofenArchives of Biochemistry and Biophysics, 1998
- The CYP2 family: models, mutants and interactionsXenobiotica, 1998
- Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359allele as low-Kmcatalysts of cyclophosphamide and ifosfamide activationPharmacogenetics, 1997
- Allelic and functional variability of cytochrome P4502C9Pharmacogenetics, 1997
- Allelic Variants of Human Cytochrome P450 2C9: Baculovirus-Mediated Expression, Purification, Structural Characterization, Substrate Stereoselectivity, and Prochiral Selectivity of the Wild-Type and I359L Mutant FormsArchives of Biochemistry and Biophysics, 1996
- Biochemistry and molecular biology of the human CYP2C subfamilyPharmacogenetics, 1994
- High–Level Expression of Human Lipocortin I in the Fission Yeast Schizosaccharomyces pombe Using a Novel Expression VectorBio/Technology, 1994
- Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liverLife Sciences, 1993
- Purification of Human Liver Cytochrome P-450 Catalyzing Testosterone 6β-Hydroxylation1The Journal of Biochemistry, 1987